Renger John 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Feb 8, 2023
Insider Transaction Report
Form 4
Renger John
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-02-06+79,022→ 79,022 totalExercise: $34.41Exp: 2033-02-06→ Common Stock (79,022 underlying) - Award
Restricted Stock Units
2023-02-06+20,081→ 20,081 total→ Common Stock (20,081 underlying)
Footnotes (3)
- [F1]25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F2]The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
- [F3]The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.